Invicro opens new global headquarters and laboratory in Needham, Mass.

0

[ad_1]

New facility meets growing demands from pharmaceutical and biotech companies developing life-changing drugs

NEEDHAM, Mass., May 5, 2022 /PRNewswire/ — Invicro LLCa part of REALM IDx, Inc.today announced the relocation of its global headquarters and the expansion of its US laboratories for radiology and pathology imaging services to Needham, Mass.to provide more resources to support pharmaceutical and biotech companies and their development of life-changing drugs.

Imaging technologies, such as MRIs, CT scans and PET scans, are an essential and growing part of patient care, including diagnosis, staging and monitoring of disease and treatment. In the development of new drugs, imaging enables personalized assessment of disease burden and drug response. Invicro’s imaging services and expanded facilities will provide more resources to pharmaceutical and biotechnology companies, delivering next-generation biomarkers backed by world-class capabilities that support new drug discovery for patient care, ranging from discovery research to global clinical trials.

“We are thrilled to move into our new Needham headquarters and to increase our ability to meet the demands of our customers,” said Matt Silva, Ph.D., CEO of Invicro. “Invicro’s mission is to visualize and quantify biological and pathological processes to better diagnose, treat and cure disease through advanced imaging, computing and operations applications. important goals. »

The new headquarters are located at 119 Fourth Avenue in Needhama suburb of Boston which is in the growing biotech corridor. The facility provides 7,000 square feet of additional laboratory space over the previous headquarters, allowing Invicro to continue to evolve its pharmacology, pathology, chemistry and imaging services. It also includes a new state-of-the-art MRI system that complements Invicro’s industry-leading PET and SPECT applications. In addition, this move allows Invicro to increase access to radiochemistry services and therapeutic radioisotopes. Invicro’s Advanced Pathology Services Group has expanded its lab footprint to complement its new 3,000+ square foot CLIA/CAP accredited pathology services lab at Aliso Viejo, Calif. This expansion allows the pathology team to strengthen its tissue imaging capabilities, including histopathology, immunohistochemistry (IHC) and new methods all of which improve visualization, sensitivity and quantification.

Invicro is a global provider of imaging biomarkers, basic laboratory and pathology services, advanced analytics and software solutions for drug discovery and development. The company operates from eight global laboratories, clinics and sites, including Massachusetts, Michigan and California in United Statesand the UK, India and Japan internationally.

About Invicro

Based at Needham, Mass., Invicro was founded in 2008 with a mission to enhance the role and function of imaging in translational drug discovery and development across all therapeutic areas. Today, Invicro’s multidisciplinary team provides solutions to pharmaceutical and biotechnology companies at all stages of the drug development pipeline (Phase 0-IV), all imaging modalities and all therapeutic areas, including neurology, oncology and systemic and rare diseases. Invicro’s quantitative biomarker services, advanced analytics and AI tools, and clinical operational services are supported by Invicro’s VivoQuant® and iPACS® software computing platforms, as well as their platform pioneering IQ-Analytics, which includes AmyloidIQTauIQ and DaTIQ.

Invicro is part of REALM IDx, Inc., a healthcare company pioneering integrated diagnostics, a new frontier of advanced clinical science that brings together laboratory medicine, radiology, pathology and sophisticated artificial intelligence to gain actionable insights that can lead to better medical solutions for patient care.

Media Contact
Brad Lotterman
Communications Director
REALM IDx, Inc.
[email protected]
760-579-3509

SOURCEInvicro

[ad_2]
Source link

Share.

Comments are closed.